145 related articles for article (PubMed ID: 27117227)
1. Managing Hodgkin lymphoma without chemotherapy: a novel, yet 'welcomed', challenge.
Kourie HR; Tabchi S; Kattan J
Future Oncol; 2016 Jun; 12(12):1435-7. PubMed ID: 27117227
[No Abstract] [Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
4. New drugs and targeted treatments in Hodgkin's lymphoma.
Provencio M; Sánchez A; Sánchez-Beato M
Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
[TBL] [Abstract][Full Text] [Related]
6. Novel agents for the treatment of Hodgkin lymphoma.
Dumaswala K; Mehta A
Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
Illés Á; Jóna Á; Miltényi Z
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
Zhao L; Yang Y; Li W; Li T; Gao Q
Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in classical Hodgkin lymphoma.
Borchmann S; von Tresckow B
Leuk Lymphoma; 2017 Oct; 58(10):2275-2286. PubMed ID: 28318345
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?
Canellos GP
J Clin Oncol; 2012 Jun; 30(18):2171-2. PubMed ID: 22547611
[No Abstract] [Full Text] [Related]
16. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].
Rossi C; Bastie JN
Rev Med Interne; 2019 Apr; 40(4):246-254. PubMed ID: 29801709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
